Sign In
Buy IMNM
$19.81
+0.470 (+2.43%)
At Close: Jun 03, 2026
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced detailed eff
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
09:00am, Wednesday, 27'th May 2026
[url="]Immunome[/url], Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ann
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
08:00am, Wednesday, 27'th May 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members o
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
04:02pm, Tuesday, 12'th May 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 05'th May 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
07:30am, Wednesday, 29'th Apr 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submissi
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
10:30am, Tuesday, 21'st Apr 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today annou
Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead
04:54pm, Tuesday, 14'th Apr 2026
Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation of its recovery trend with upside momentum building toward prior highs.
Max Rosett Sells 65,000 Shares of Immunome (NASDAQ:IMNM) Stock
04:50am, Sunday, 05'th Apr 2026
Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
07:05pm, Saturday, 04'th Apr 2026
9,438 shares were sold for a transaction value of ~$204,000 on April 2, 2026. This sale represented 30.02% of Higgins's holdings at the time.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Thursday, 02'nd Apr 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
09:01am, Wednesday, 01'st Apr 2026
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d
Immunome: Upcoming NDA, Valuation, And Investment Case
12:51am, Wednesday, 11'th Mar 2026
Immunome is advancing varegacestat for desmoid tumors, targeting NDA submission in Q2 2026 after positive phase 3 RINGSIDE data. Varegacestat demonstrated superior efficacy and safety versus nirogaces
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Thursday, 05'th Mar 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
